WO2019035705A3 - Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel - Google Patents

Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel Download PDF

Info

Publication number
WO2019035705A3
WO2019035705A3 PCT/MX2018/000071 MX2018000071W WO2019035705A3 WO 2019035705 A3 WO2019035705 A3 WO 2019035705A3 MX 2018000071 W MX2018000071 W MX 2018000071W WO 2019035705 A3 WO2019035705 A3 WO 2019035705A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
chronic skin
pirfenidone
skin damage
composition containing
Prior art date
Application number
PCT/MX2018/000071
Other languages
English (en)
French (fr)
Other versions
WO2019035705A2 (es
Inventor
José Agustín Rogelio MAGAÑA CASTRO
Juan Socorro ARMENDÁRIZ BORUNDA
Original Assignee
Cell Therapy and Technology S.A. DE C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16/638,621 priority Critical patent/US11576905B2/en
Priority to AU2018317188A priority patent/AU2018317188B2/en
Priority to JP2020508593A priority patent/JP2020531455A/ja
Priority to RU2020110783A priority patent/RU2020110783A/ru
Application filed by Cell Therapy and Technology S.A. DE C.V. filed Critical Cell Therapy and Technology S.A. DE C.V.
Priority to EP18839550.3A priority patent/EP3714872A2/en
Priority to CN201880066604.2A priority patent/CN111246840A/zh
Priority to CA3072855A priority patent/CA3072855A1/en
Priority to SG11202002214QA priority patent/SG11202002214QA/en
Priority to BR112020003001-5A priority patent/BR112020003001A2/pt
Priority to KR1020207007458A priority patent/KR20200091379A/ko
Publication of WO2019035705A2 publication Critical patent/WO2019035705A2/es
Publication of WO2019035705A3 publication Critical patent/WO2019035705A3/es
Priority to ECSENADI202010477A priority patent/ECSP20010477A/es
Priority to PH12020500324A priority patent/PH12020500324A1/en
Priority to JP2023065867A priority patent/JP2023080289A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona composiciones de gel tópicas farmacéuticas para el tratamiento de daños crónicos de la piel, específicamente para los daños causados por úlceras neuropáticas y preferentemente para el tratamiento del pie diabético y en el tratamiento de úlceras vasculares, en donde dichas composiciones comprenden una combinación de Dialil Óxido de Disulfuro Modificado (ODD-M) (como agente antiséptico/antibiótico) y 5-metil-1-fenil-2(1H)-piridona. Además, la invención describe métodos de tratamiento, aplicaciones y/o usos farmacéuticos en la preparación de medicamentos para eliminar, reducir o prevenir lesiones crónicas de la piel y los daños causados por úlceras neuropáticas y particularmente en el tratamiento del pie diabético y en el tratamiento de úlceras vasculares.
PCT/MX2018/000071 2017-08-15 2018-08-10 Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel WO2019035705A2 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201880066604.2A CN111246840A (zh) 2017-08-15 2018-08-10 用于治疗慢性皮肤损伤的包含抗微生物剂和吡非尼酮的局部半固体组合物
JP2020508593A JP2020531455A (ja) 2017-08-15 2018-08-10 慢性皮膚損傷の治療のための抗微生物剤とピルフェニドンとを含有する局所用半固体組成物
RU2020110783A RU2020110783A (ru) 2017-08-15 2018-08-10 Полутвердая композиция для наружного применения, содержащая антимикробный агент и пирфенидон для лечения хронического повреждения кожи
SG11202002214QA SG11202002214QA (en) 2017-08-15 2018-08-10 Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
EP18839550.3A EP3714872A2 (en) 2017-08-15 2018-08-10 Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
AU2018317188A AU2018317188B2 (en) 2017-08-15 2018-08-10 Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
CA3072855A CA3072855A1 (en) 2017-08-15 2018-08-10 Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
US16/638,621 US11576905B2 (en) 2017-08-15 2018-08-10 Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
BR112020003001-5A BR112020003001A2 (pt) 2017-08-15 2018-08-10 composição semissólida tópica contendo um agente antimicrobiano e pirfenidona para o tratamento de danos crônicos na pele
KR1020207007458A KR20200091379A (ko) 2017-08-15 2018-08-10 만성 피부 손상의 치료를 위한 항미생물제 및 피르페니돈을 함유하는 국소 반고체 조성물
ECSENADI202010477A ECSP20010477A (es) 2017-08-15 2020-02-12 Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel
PH12020500324A PH12020500324A1 (en) 2017-08-15 2020-02-13 Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
JP2023065867A JP2023080289A (ja) 2017-08-15 2023-04-13 慢性皮膚損傷の治療のための抗微生物剤とピルフェニドンとを含有する局所用半固体組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2017010486A MX366086B (es) 2017-08-15 2017-08-15 Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MXMX/A/2017/010486 2017-08-15

Publications (2)

Publication Number Publication Date
WO2019035705A2 WO2019035705A2 (es) 2019-02-21
WO2019035705A3 true WO2019035705A3 (es) 2019-05-09

Family

ID=64605095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2018/000071 WO2019035705A2 (es) 2017-08-15 2018-08-10 Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel

Country Status (15)

Country Link
US (1) US11576905B2 (es)
EP (1) EP3714872A2 (es)
JP (2) JP2020531455A (es)
KR (1) KR20200091379A (es)
CN (1) CN111246840A (es)
AR (1) AR112474A1 (es)
AU (1) AU2018317188B2 (es)
BR (1) BR112020003001A2 (es)
CA (1) CA3072855A1 (es)
EC (1) ECSP20010477A (es)
MX (1) MX366086B (es)
PH (1) PH12020500324A1 (es)
RU (1) RU2020110783A (es)
SG (1) SG11202002214QA (es)
WO (1) WO2019035705A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
RU2753638C2 (ru) * 2020-01-24 2021-08-18 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НОВАСКИН" (ООО "Новаскин") Гелевая композиция для обработки кожных покровов

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047140A1 (en) * 1998-03-17 1999-09-23 Margolin Solomon B Topical antiseptic compositions and methods
EP1113798A1 (en) * 1998-09-18 2001-07-11 Max Werner Scheiwe Topical formulation of alkyl-, phenyl-pyridone
EP2832354A1 (en) * 2012-03-28 2015-02-04 Cell Therapy and Technology S.A. de C.V. Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
IL124454A (en) 1995-12-21 2003-10-31 Pfizer Injectable danofloxacin formulations
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
IN191090B (es) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
CH696420A5 (de) * 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
WO2004073713A1 (ja) 2003-02-21 2004-09-02 Shionogi & Co., Ltd. ピルフェニドンのゲル剤
WO2005062739A2 (en) 2003-05-23 2005-07-14 Ott David M S-allylmercaptocysteine prodrugs and methods of treatment
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CN100542532C (zh) 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
SI1928454T1 (sl) 2005-05-10 2015-01-30 Intermune, Inc. Piridonski derivati za moduliranje s stresom aktiviranega protein kinaznega sistema
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US8586078B2 (en) 2005-12-05 2013-11-19 Rba Pharma Inc. Emulsion-containing medical articles
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
CA2679700A1 (en) 2007-03-02 2008-09-12 Talia Miron Mercaptopurine derivatives as anticancer agents
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
KR101767849B1 (ko) 2007-06-20 2017-08-11 오스펙스 파마슈티칼스, 인코포레이티드 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US20090137354A1 (en) 2007-11-27 2009-05-28 Shimano Inc. Bicycle rear derailleur
EP2628747A1 (en) 2007-12-11 2013-08-21 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100256031A1 (en) 2008-10-10 2010-10-07 Jeffrey Wu Shine control cleanser
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972225A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的凝胶组合物
CN101972236A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
ES2913095T3 (es) 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
CN102670632A (zh) 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX2012003874A (es) 2012-03-30 2012-11-19 Moleculas Naturales S A De C V Procedimiento para la obtencion del complejo de cloruro de benzalconio-dialil oxido de disulfuro modificado en uso como biocida.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
MX352342B (es) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos.
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
KR20180093932A (ko) 2015-12-16 2018-08-22 다이이찌 산쿄 가부시키가이샤 창상 치료제
MX364040B (es) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047140A1 (en) * 1998-03-17 1999-09-23 Margolin Solomon B Topical antiseptic compositions and methods
EP1113798A1 (en) * 1998-09-18 2001-07-11 Max Werner Scheiwe Topical formulation of alkyl-, phenyl-pyridone
EP2832354A1 (en) * 2012-03-28 2015-02-04 Cell Therapy and Technology S.A. de C.V. Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne

Also Published As

Publication number Publication date
WO2019035705A2 (es) 2019-02-21
EP3714872A2 (en) 2020-09-30
AU2018317188B2 (en) 2024-08-29
KR20200091379A (ko) 2020-07-30
MX366086B (es) 2019-06-27
CN111246840A (zh) 2020-06-05
JP2023080289A (ja) 2023-06-08
US11576905B2 (en) 2023-02-14
PH12020500324A1 (en) 2020-09-28
SG11202002214QA (en) 2020-04-29
AU2018317188A1 (en) 2020-04-02
RU2020110783A (ru) 2021-09-16
MX2017010486A (es) 2018-09-21
ECSP20010477A (es) 2020-04-22
AR112474A1 (es) 2019-10-30
CA3072855A1 (en) 2019-02-21
US20200253944A1 (en) 2020-08-13
RU2020110783A3 (es) 2021-12-08
JP2020531455A (ja) 2020-11-05
BR112020003001A2 (pt) 2020-08-11

Similar Documents

Publication Publication Date Title
PH12020500324A1 (en) Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
AU2016245785A8 (en) Synergistic preservative compositions
WO2012017349A3 (en) Topical pharmaceutical composition comprising nanonized silver sulfadiazine and chlorhexidine gluconate
WO2015002932A8 (en) Antimicrobial compositions comprising hypochlorous acid and silver
MX2011010781A (es) Una crema medicinal hecha con sulfadiazina de plata y quitosano y un proceso para hacerla.
MX2012013606A (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
MX2021001276A (es) Composiciones de bismuto-tiol y metodos para tratar heridas.
EA201401031A1 (ru) Полутвёрдая композиция для местного применения, которая содержит пирфенидон и модифицированный диаллилдисульфид оксид (m-ddo) для удаления или предупреждения угрей
EP4108242A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING A MTOR SIGNALING INHIBITOR AS ACTIVE INGREDIENT
WO2014179318A3 (en) Antimicrobials and methods of use thereof for wound healing
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
FR2978665B1 (fr) Composition antiseptique
WO2016159593A3 (ko) 락토코커스 중앙젠시스를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2014030992A3 (es) Composición antiséptica, seborreguladora y exfoliante para tratar o prevenir el acné
EP4169531A4 (en) MEDICINAL PRODUCT WITH ACTIVE SULFUR COMPOUND AS MAIN INGREDIENT
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
EP4166156A4 (en) COMPOSITION FOR THE PREVENTION, MITIGATION OR TREATMENT OF ALLERGIC DISEASES OR PRURITUS WITH PENTAPEPTIDE AS THE ACTIVE INGREDIENT
EP3327000A4 (en) NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, CONTAINING THE SAME AS ACTIVE INGREDIENT
EP4005572A4 (en) BENZAMIDE DERIVATIVE, METHOD FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF CANCER
WO2018094023A3 (en) Cyclic dipeptides and wound healing
EP3895719A4 (en) PHARMACEUTICAL COMPOSITION WITH LACTOBACILLUS SAKEI WIKIM30 AS AN ACTIVE SUBSTANCE TO PREVENT OR TREAT CANCER
EP3949963A4 (en) NEW COMPOUND AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES COMPRISING THIS AS AN ACTIVE PRINCIPLE
MX2019011951A (es) Secretoma bacteriano para usarse en el tratamiento contra lesiones cutaneas.
EP4173641A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE RETINAL DISEASES, COMPRISING A PROX1 INHIBITOR AS ACTIVE INGREDIENT

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 3072855

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020508593

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020003001

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018839550

Country of ref document: EP

Effective date: 20200316

ENP Entry into the national phase

Ref document number: 2018317188

Country of ref document: AU

Date of ref document: 20180810

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18839550

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112020003001

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200212